ESMO: Gilead’s Trodelvy Outperforms Expectations In Breast Cancer, Again

 
• By Alaric DeArment

The company is presenting overall survival data in HR+/HER2- breast cancer from the TROPiCS-02 at ESMO. Oncology clinical development head Bill Grossman talked with Scrip about how it differs from rival Enhertu.

OS data from Gilead's TROPiCS-02 trial exceeded the expectations of many investors • Source: Shutterstock

More from Anticancer

More from Therapy Areas